Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome

Scand Cardiovasc J. 2007 Jun;41(3):149-54. doi: 10.1080/14017430601164263.

Abstract

Objectives: To investigate the association between inflammatory mediators, matrix degrading enzymes and acute coronary syndrome (ACS) and the impact of early reperfusion therapy on circulating biomarkers.

Design: Peripheral serum levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) were determined in 134 patients with ACS. These biomarkers were serially monitored in ten patients with intravenous thrombolytic therapy (IVT).

Results: Serum levels of IL-6, hs-CRP and MMP-9 were higher in unstable angina (UA) and myocardial infarction (MI) groups than in control or SA group (p<0.05). Peripheral IL-6 level in patients with MI was greater after percutaneous coronary intervention (PCI) (p<0.01) or IVT (p<0.05). Serial concentration determination revealed marked elevation of serum IL-6 and MMP-9 levels, both reaching peak values (like creatine kinase-MB).

Conclusions: Elevated levels of IL-6, hs-CRP and MMP-9 provide a link between inflammation, matrix degradation and the development and progression of ACS. IL-6 and MMP-9 appear to be released mainly from vulnerable plaque or necrotic myocardium during the acute phase of MI.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon, Coronary
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Creatine Kinase, MB Form / blood
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Interleukin-6 / blood*
  • Male
  • Matrix Metalloproteinase 9 / blood*
  • Middle Aged
  • Myocardial Ischemia / enzymology
  • Myocardial Ischemia / metabolism*
  • Myocardial Ischemia / therapy
  • Myocardium / enzymology
  • Myocardium / metabolism*
  • Research Design
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Fibrinolytic Agents
  • IL6 protein, human
  • Interleukin-6
  • C-Reactive Protein
  • Creatine Kinase, MB Form
  • Matrix Metalloproteinase 9